MBRX: Moleculin Biotech, Inc. Stock

by  •  • Comments Off on MBRX: Moleculin Biotech, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.30
Enterprise Value ($M) -6.10
Book Value ($M) 7.48
Book Value / Share 2.49
Price / Book 0.44
NCAV ($M) -4.31
NCAV / Share -1.44
Price / NCAV -0.77

Profitability (mra)
Return on Invested Capital (ROIC) -3.78
Return on Assets (ROA) -0.79
Return on Equity (ROE) -1.16

Liquidity (mrq)
Quick Ratio 2.08
Current Ratio 2.08

Balance Sheet (mrq) ($M)
Current Assets 11.61
Assets 23.39
Liabilities 15.91
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc 9.99 12.88

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-04-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPO
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 171,311 573,517 29.87
2025-03-06 252,261 660,688 38.18
2025-03-05 348,955 797,934 43.73
2025-03-04 341,073 972,821 35.06

(click for more detail)

Similar Companies
LSTA – Lisata Therapeutics, Inc. LTRN – Lantern Pharma Inc.
MBIO – Mustang Bio, Inc. ME – 23andMe Holding Co.
MEIP – MEI Pharma, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Moleculin Biotech